Published in Oncologist on January 01, 2011
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. J Clin Oncol (2014) 2.78
Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence. Oncologist (2011) 1.92
Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST. AJR Am J Roentgenol (2012) 1.69
Polypeptide N-acetylgalactosaminyl transferase 3 independently predicts high-grade tumours and poor prognosis in patients with renal cell carcinomas. Br J Cancer (2013) 1.06
Current status of targeted therapy for advanced renal cell carcinoma. Korean J Urol (2012) 1.02
Cancer stem cell-like side population cells in clear cell renal cell carcinoma cell line 769P. PLoS One (2013) 1.00
Absent Toll-like receptor-9 expression predicts poor prognosis in renal cell carcinoma. J Exp Clin Cancer Res (2011) 0.98
DACH1 inhibits cyclin D1 expression, cellular proliferation and tumor growth of renal cancer cells. J Hematol Oncol (2014) 0.96
Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells. Br J Cancer (2014) 0.89
Functional genomics identifies novel genes essential for clear cell renal cell carcinoma tumor cell proliferation and migration. Oncotarget (2014) 0.89
TRIM8 anti-proliferative action against chemo-resistant renal cell carcinoma. Oncotarget (2014) 0.89
The natural product honokiol inhibits calcineurin inhibitor-induced and Ras-mediated tumor promoting pathways. Cancer Lett (2013) 0.88
The plasma membrane sialidase NEU3 regulates the malignancy of renal carcinoma cells by controlling β1 integrin internalization and recycling. J Biol Chem (2012) 0.87
Interleukin-1β mediates metalloproteinase-dependent renal cell carcinoma tumor cell invasion through the activation of CCAAT enhancer binding protein β. Cancer Med (2012) 0.87
Increased expression of the very low-density lipoprotein receptor mediates lipid accumulation in clear-cell renal cell carcinoma. PLoS One (2012) 0.84
The expression and role of tyrosine kinase ETK/BMX in renal cell carcinoma. J Exp Clin Cancer Res (2014) 0.83
The expression and role of protein kinase C (PKC) epsilon in clear cell renal cell carcinoma. J Exp Clin Cancer Res (2011) 0.82
Ovatodiolide Targets β -Catenin Signaling in Suppressing Tumorigenesis and Overcoming Drug Resistance in Renal Cell Carcinoma. Evid Based Complement Alternat Med (2013) 0.82
Renal cell neoplasms contain shared tumor type-specific copy number variations. Am J Pathol (2012) 0.81
Indirect comparisons of efficacy and safety between seven newer targeted agents for metastatic renal cell carcinoma: A network meta-analysis of randomised clinical trials. Mol Clin Oncol (2014) 0.80
Phospho-4e-BP1 and eIF4E overexpression synergistically drives disease progression in clinically confined clear cell renal cell carcinoma. Am J Cancer Res (2015) 0.80
Prognostic markers in renal cell carcinoma: A focus on the 'mammalian target of rapamycin' pathway. Arab J Urol (2012) 0.79
Insulin receptor expression in clear cell renal cell carcinoma and its relation to prognosis. Yonsei Med J (2014) 0.78
Systemic adjuvant therapies in renal cell carcinoma. Oncol Rev (2012) 0.78
Prognostic impact of urokinase-type plasminogen activator system components in clear cell renal cell carcinoma patients without distant metastasis. BMC Cancer (2014) 0.77
Preclinical Modeling of Tumor Growth and Angiogenesis Inhibition to Describe Pazopanib Clinical Effects in Renal Cell Carcinoma. CPT Pharmacometrics Syst Pharmacol (2015) 0.77
Clinico-pathological prognostic factors of renal cell carcinoma: A 15-year review from a single center in Greece. Urol Ann (2014) 0.76
CRISPR-Mediated VHL Knockout Generates an Improved Model for Metastatic Renal Cell Carcinoma. Sci Rep (2016) 0.75
Overexpression of IL-32 is a novel prognostic factor in patients with localized clear cell renal cell carcinoma. Oncol Lett (2011) 0.75
Integration of multimodal RNA-seq data for prediction of kidney cancer survival. Proceedings (IEEE Int Conf Bioinformatics Biomed) (2015) 0.75
Influence of VEGFR single nucleotide polymorphisms on the efficacy of sunitinib therapy against renal cell carcinoma. Oncol Lett (2016) 0.75
Expression and prognostic significance of zinc fingers and homeoboxes family members in renal cell carcinoma. PLoS One (2017) 0.75
Insulin-like growth factor-1 signaling in renal cell carcinoma. BMC Cancer (2016) 0.75
Klotho plays a critical role in clear cell renal cell carcinoma progression and clinical outcome. Korean J Physiol Pharmacol (2016) 0.75
Management of metastatic renal cell carcinoma - mini review. J Kidney Cancer VHL (2015) 0.75
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
Defining the role of mTOR in cancer. Cancer Cell (2007) 21.63
Upstream and downstream of mTOR. Genes Dev (2004) 21.61
Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature (2006) 12.13
Identification of the von Hippel-Lindau disease tumor suppressor gene. Science (1993) 11.95
Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet (1994) 10.14
Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol (2002) 9.05
Phosphoinositide kinases. Annu Rev Biochem (1998) 8.51
Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. Cell (2000) 8.34
Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res (2006) 8.21
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol (2009) 8.16
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet (1997) 6.83
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell (2003) 6.59
PI3K/Akt signalling pathway and cancer. Cancer Treat Rev (2004) 5.46
Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science (1995) 4.93
HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell (2008) 4.84
Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol (1995) 4.42
Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol (2001) 4.22
Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum Mol Genet (2005) 4.12
The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Natl Acad Sci U S A (1997) 3.75
Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res (2005) 3.74
Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc Natl Acad Sci U S A (2006) 3.51
Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol (2005) 3.49
Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res (2003) 3.25
A postoperative prognostic nomogram for renal cell carcinoma. J Urol (2001) 3.01
Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene (1999) 3.01
Birt-Hogg-Dubé syndrome, a genodermatosis associated with spontaneous pneumothorax and kidney neoplasia, maps to chromosome 17p11.2. Am J Hum Genet (2001) 2.68
Vascular endothelial growth factor as a target for anticancer therapy. Oncologist (2004) 2.65
Phosphatidylinositol-3-kinase/Akt signaling pathway and kidney cancer, and the therapeutic potential of phosphatidylinositol-3-kinase/Akt inhibitors. J Urol (2009) 2.43
Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer (2007) 2.25
The role of the Birt-Hogg-Dubé protein in mTOR activation and renal tumorigenesis. Oncogene (2009) 2.14
Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol (2007) 2.09
Engineered lentivector targeting of dendritic cells for in vivo immunization. Nat Biotechnol (2008) 2.05
Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma. Cancer (2009) 2.00
Identification and characterization of a novel folliculin-interacting protein FNIP2. Gene (2008) 1.82
Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J Immunother (2005) 1.78
Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer (2008) 1.70
Hypoxia-inducible factor 1alpha expression in renal cell carcinoma analyzed by tissue microarray. Eur Urol (2006) 1.66
Deficiency of FLCN in mouse kidney led to development of polycystic kidneys and renal neoplasia. PLoS One (2008) 1.64
Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. Clin Cancer Res (2007) 1.61
Therapeutic targets: MTOR and related pathways. Cancer Biol Ther (2006) 1.57
Renal tumour suppressor function of the Birt-Hogg-Dubé syndrome gene product folliculin. J Med Genet (2009) 1.57
Specific genetic change in tumors associated with von Hippel-Lindau disease. J Natl Cancer Inst (1989) 1.56
Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma. J Clin Oncol (2009) 1.55
Using protein expressions to predict survival in clear cell renal carcinoma. Clin Cancer Res (2004) 1.51
Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol (2000) 1.35
Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib. Anticancer Drugs (2010) 1.34
Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. Clin Cancer Res (2010) 1.30
Molecular cytogenetics of renal cell tumors. Adv Cancer Res (1993) 1.29
Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy. Cancer Epidemiol Biomarkers Prev (2009) 1.23
Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha. Cancer (2009) 1.21
Renal cell carcinoma: antitumor effects of leukocyte interferon. Cancer Res (1983) 1.17
Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma. Clin Cancer Res (2009) 1.16
The expression of hypoxia-inducible factor 1alpha is a favorable independent prognostic factor in renal cell carcinoma. Clin Cancer Res (2005) 1.15
Enhancing mTOR-targeted cancer therapy. Expert Opin Ther Targets (2009) 1.13
mTOR in renal cell cancer: modulator of tumor biology and therapeutic target. Expert Rev Mol Diagn (2009) 1.08
A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings. Cancer Immunol Immunother (2010) 1.08
The anti-angiogenic isoforms of VEGF in health and disease. Biochem Soc Trans (2009) 1.07
Prognostic assessment of nonmetastatic renal cell carcinoma: a clinically based model. Urology (2001) 1.03
Genetic basis for kidney cancer: opportunity for disease-specific approaches to therapy. Expert Opin Biol Ther (2008) 0.96
Detection of circulating tumor cells in peripheral blood of patients with renal cell carcinoma correlates with prognosis. Cancer Epidemiol Biomarkers Prev (2009) 0.93
Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor. Cancer Res (2001) 0.92
Significance of P-glycoprotein, p53, and survivin expression in renal cell carcinoma. Urol Oncol (2009) 0.92
Circulating tumor M2 pyruvate kinase and thymidine kinase 1 are potential predictors for disease recurrence in renal cell carcinoma after nephrectomy. Urology (2010) 0.91
The prognostic significance of COX-2 and survivin expression in ovarian cancer. Pathol Res Pract (2008) 0.90
Survivin expression in renal cell carcinoma. Cancer Invest (2008) 0.89
Molecular biology of renal cortical tumors. Urol Clin North Am (2008) 0.89
Novel kidney cancer immunotherapy based on the granulocyte-macrophage colony-stimulating factor and carbonic anhydrase IX fusion gene. Clin Cancer Res (2003) 0.87
Prognostic value of the co-expression of carbonic anhydrase IX and vascular endothelial growth factor in patients with clear cell renal cell carcinoma. Oncol Rep (2008) 0.87
Expression of hypoxia inducible factor-1α and 2α in conventional renal cell carcinoma with or without sarcomatoid differentiation. Urol Oncol (2009) 0.87
Genetic basis of bilateral renal cancer: implications for evaluation and management. J Clin Oncol (2009) 0.83
The treatment of renal cell carcinoma with human leukocyte alpha-interferon. J Urol (1983) 0.81
Circulating endothelial cells and progenitors: potential biomarkers of renal cell carcinoma. BJU Int (2010) 0.78
Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am (2003) 3.44
Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res (2003) 3.25
Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol (2005) 3.15
Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. J Urol (2004) 3.06
Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int (2005) 3.06
Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol (2002) 2.91
Gene signatures of progression and metastasis in renal cell cancer. Clin Cancer Res (2005) 2.67
Tumor size does not predict risk of metastatic disease or prognosis of small renal cell carcinomas. J Urol (2008) 2.45
Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery. Eur Urol (2009) 2.41
Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer (2007) 2.38
Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU Int (2008) 2.35
Prognostic factors and predictive models in renal cell carcinoma: a contemporary review. Eur Urol (2011) 2.10
Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urol (2005) 2.05
Novel approaches in the therapy of metastatic renal cell carcinoma. World J Urol (2005) 2.05
Tumor classification by tissue microarray profiling: random forest clustering applied to renal cell carcinoma. Mod Pathol (2005) 1.89
Secondary hormonal therapy for advanced prostate cancer. J Urol (2006) 1.86
p21 is a prognostic marker for renal cell carcinoma: implications for novel therapeutic approaches. J Urol (2007) 1.81
Cytoreductive nephrectomy for kidney cancer with sarcomatoid histology--is up-front resection indicated and, if not, is it avoidable? J Urol (2009) 1.75
Prognostic significance of venous thrombus in renal cell carcinoma. Are renal vein and inferior vena cava involvement different? J Urol (2004) 1.70
Prognostic relevance of capsular involvement and collecting system invasion in stage I and II renal cell carcinoma. BJU Int (2007) 1.69
Prognostic impact of tumor size on pT2 renal cell carcinoma: an international multicenter experience. J Urol (2007) 1.67
Comparisons of percent equol producers between prostate cancer patients and controls: case-controlled studies of isoflavones in Japanese, Korean and American residents. Jpn J Clin Oncol (2004) 1.65
Smoking negatively impacts renal cell carcinoma overall and cancer-specific survival. Cancer (2011) 1.64
Prognostic value of microvascular invasion in predicting the cancer specific survival and risk of metastatic disease in renal cell carcinoma: a multicenter investigation. J Urol (2011) 1.63
Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. Clin Cancer Res (2007) 1.61
Histologic evaluation of metastases in renal cell carcinoma with sarcomatoid transformation and its implications for systemic therapy. Cancer (2010) 1.61
Use of American Society of Anesthesiologists physical status classification to assess perioperative risk in patients undergoing radical nephrectomy for renal cell carcinoma. Urology (2004) 1.60
Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J Urol (2005) 1.60
Treatment of organ confined prostate cancer with third generation cryosurgery: preliminary multicenter experience. J Urol (2003) 1.60
Dominant B cell epitope from NY-ESO-1 recognized by sera from a wide spectrum of cancer patients: implications as a potential biomarker. Int J Cancer (2005) 1.59
Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. J Urol (2003) 1.59
Intraoperative thrombus embolization during nephrectomy and tumor thrombectomy: critical analysis of the University of California-Los Angeles experience. J Urol (2008) 1.59
Performance status and cytoreductive nephrectomy: redefining management in patients with poor performance. Cancer (2008) 1.58
Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. Clin Cancer Res (2003) 1.57
Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma. J Clin Oncol (2009) 1.55
CA9 gene: single nucleotide polymorphism predicts metastatic renal cell carcinoma prognosis. J Urol (2009) 1.54
Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival. Cancer (2008) 1.53
Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis. J Urol (2003) 1.52
Salvage-targeted kidney cancer therapy in patients progressing on high-dose interleukin-2 immunotherapy: the UCLA experience. Cancer J (2013) 1.52
Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol (2004) 1.52
Platelet count and preoperative haemoglobin do not significantly increase the performance of established predictors of renal cell carcinoma-specific mortality. Eur Urol (2007) 1.51
Using protein expressions to predict survival in clear cell renal carcinoma. Clin Cancer Res (2004) 1.51
PC-SPES: herbal formulation for prostate cancer. Urology (2002) 1.48
Sex, age, and surgeon decision on nephron-sparing surgery are independent predictors of renal masses with benign histologic findings--a multicenter survey. Urology (2010) 1.46
Fuhrman grade provides higher prognostic accuracy than nucleolar grade for papillary renal cell carcinoma. J Urol (2010) 1.44
Pathological, immunohistochemical and cytogenetic features of papillary renal cell carcinoma with clear cell features. J Urol (2010) 1.43
Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Int J Cancer (2008) 1.43
Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. J Urol (2004) 1.42
Pomegranate ellagitannin-derived metabolites inhibit prostate cancer growth and localize to the mouse prostate gland. J Agric Food Chem (2007) 1.41
Surveillance strategies for renal cell carcinoma patients following nephrectomy. Rev Urol (2006) 1.41
The prevalence of malignancy in satellite renal lesions and its surgical implication during nephron sparing surgery. J Urol (2007) 1.38
Ureteral tumor thrombus from renal cell carcinoma extending into bladder. Urol Oncol (2007) 1.36
Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies. Clin Cancer Res (2008) 1.34
Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies. Cancer (2008) 1.32
Changing concepts in the management of renal oncocytoma. Urology (2002) 1.31
Collecting duct renal cell carcinoma: clinical study of a rare tumor. J Urol (2002) 1.31
Clear cell renal cell carcinoma: discrimination from other renal cell carcinoma subtypes and oncocytoma at multiphasic multidetector CT. Radiology (2013) 1.30
Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy. Cancer (2003) 1.29
Epithelial cell adhesion molecule (KSA) expression: pathobiology and its role as an independent predictor of survival in renal cell carcinoma. Clin Cancer Res (2004) 1.27
Mathematical model to predict individual survival for patients with renal cell carcinoma. J Clin Oncol (2002) 1.27
Renal cell carcinoma with tumor thrombus extension: biology, role of nephrectomy and response to immunotherapy. J Urol (2003) 1.25
Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys (2004) 1.25